Catridecacog

Summary

Catridecacog (CHEMBL2108282) is an approved protein (ATC B02BD11); indicated across 4 conditions including inherited blood coagulation disorder and factor xiii deficiency.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B02BD11
• Indications: 4 conditions
• Clinical trials: 13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108282
Name	Catridecacog
Type	Protein
Max phase	4
ATC	B02BD11

Also known as: Catridecacog, Novothirteen, Tretten, CATRIDECACOG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
inherited blood coagulation disorder	4	MONDO:0021181	Orphanet:183654
factor XIII deficiency	3	MONDO:0002241	MONDO:0018029
hemorrhagic disease	2	MONDO:0002243	MONDO:0002243

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
PHASE1	6
PHASE3	4
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00713648	PHASE3	COMPLETED	Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
NCT00978380	PHASE3	COMPLETED	Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
NCT01230021	PHASE3	COMPLETED	Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
NCT01253811	PHASE3	COMPLETED	Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
NCT00914589	PHASE2	COMPLETED	Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
NCT01706159	PHASE2	TERMINATED	A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
NCT00056589	PHASE1	COMPLETED	Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
NCT01082406	PHASE1	COMPLETED	Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects
NCT01153997	PHASE1	COMPLETED	Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
NCT01847989	PHASE1	COMPLETED	Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
NCT01848002	PHASE1	COMPLETED	Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
NCT02239146	PHASE1	COMPLETED	Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
NCT01862367	Not specified	COMPLETED	Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).